Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.